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1246Objectives: Patients with severe ischemic cardiomyopathy (left ventricular ejection fraction<25%) and severe
ischemic mitral regurgitation have a poor survival with medical therapy alone. Left ventricular assist device as
destination therapy is reserved for patients who are too high risk for conventional surgery. We evaluated our out-
comes with conventional surgery within this population and the comparative effectiveness of these 2 therapies.
Methods:We identified patients who underwent conventional surgery or left ventricular assist device as desti-
nation therapy for severe ischemic cardiomyopathy (left ventricular ejection fraction<25%) and severe mitral
regurgitation. The era for conventional surgery spanned from 1993 to 2009 and from 2007 to 2011 for left ven-
tricular assist device as destination therapy. We compared baseline patient characteristics and outcomes in terms
of end-organ function and survival.
Results: A total of 88 patients were identified; 55 patients underwent conventional surgery (63%), and 33 pa-
tients (37%) received a left ventricular assist device as destination therapy. Patients who received left ventricular
assist device as destination therapy had the increased prevalence of renal failure, inotrope dependency, and
intra-aortic balloon support. Patients undergoing conventional surgery required longer ventilatory support,
and patients receiving a left ventricular assist device required more reoperation for bleeding. Mortality rates
were similar between the 2 groups at 30 days (7% in the conventional surgery group vs 3% in the left ventricular
assist device as destination therapy group, P¼ .65) and at 1 year (22% in the conventional surgery group vs 15%
in the left ventricular assist device as destination therapy group, P ¼ .58). There was a trend toward improved
survival in patients receiving a left ventricular assist device compared with the propensity-matched groups at
1 year (94% vs 71%, P ¼ .171).
Conclusions: The operative mortality and early survival after conventional surgery seem to be acceptable. For
inoperable or prohibitive-risk patients, left ventricular assist device as destination therapy can be offered with
similar outcomes. (J Thorac Cardiovasc Surg 2014;147:1246-50)The presence ofmitral regurgitation (MR) in the setting of left
ventricular (LV) dysfunction is associated with increased
mortality.1,2 With improvements in surgical techniques,
mitral valve (MV) surgery for severe MR in the setting of
advanced LV dysfunction has become an accepted option.3,4
However, in patients with severe ischemic cardiomyopathy,
the surgical treatment of severe MR is still associated with
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The Journal of Thoracic and Cardiovascular SurAlthough studies have suggested a potential survival ad-
vantage of MV repair over replacement, ongoing debates
remain regarding the effectiveness of mitral surgery in
patients with end-stage ischemic cardiomyopathy6 and
factors that really influence survival.7 Nonetheless, the
management of patients with severe ischemic mitral regur-
gitation (IMR) and severe ischemic cardiomyopathy re-
mains challenging and is still associated with poor
outcomes.8
Left ventricular assist devices (LVADs) have become the
standard of care for patients with life-threatening heart fail-
ure refractory to optimal medical therapy.9 The HeartMate
II LVAD (Thoratec, Pleasanton, Calif) has been approved
for use as destination (permanent) therapy (DT) for patients
with end-stage congestive heart failure who are ineligible
for heart transplantation because of age, additional health
problems, or other complications.10 Thus, the use of
mechanical support devices in adult patients has recently
become commonplace in many centers, and excellent re-
ported outcomes have allowed the widespread use of thegery c April 2014
Abbreviations and Acronyms
CABG ¼ coronary artery bypass grafting
CS ¼ conventional surgery
DT ¼ destination therapy
IABP ¼ intra-aortic balloon pump
IMR ¼ ischemic mitral regurgitation
LV ¼ left ventricular
LVAD ¼ left ventricular assist device
LVEF ¼ left ventricular ejection fraction
MR ¼ mitral regurgitation
MV ¼ mitral valve
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cardiomyopathy.10
We conducted this study to understand the surgical re-
sults in patients with severe ischemic cardiomyopathy and
severe IMR. The primary objective of this study was to
evaluate surgical results in patients with severe ischemic
LV dysfunction (left ventricular ejection fraction [LVEF]
25%) and severe IMR. The secondary objective was to
compare the effectiveness of conventional surgery (CS)
(coronary artery bypass grafting [CABG] þ MV surgery)
versus LVAD as DT in this high-risk population.
PATIENTS AND METHODS
Study Design
This is a retrospective analysis of prospectively gathered data over more
than a 10-year period (median, 3.6 years; range, 0-15 years). The Mayo
Foundation Institutional Review Board approved this study, and individual
consent was obtained for all patients included in this study. For patients in
the conventional CABGþMV surgery group, the cardiac surgery database
(1993 to 2009) at Mayo Clinic (Rochester, Minn) was used to identify
a homogeneous study cohort of patients who underwent cardiac surgery
for ischemic heart disease with severe IMR.We identified patients who un-
derwent a combined CABG and MV repair or MV replacement first. Then,
we excluded those who have had any one of the following conditions:
LVEF greater than 25%, concomitant mitral prolapse, infective endocardi-
tis, congenital valvular heart disease, rheumatic valvular disease, or any
degree of mitral stenosis. We used the same cardiac surgery database
(2007-2011) to identify patients with end-stage ischemic cardiomyopathy
with severe IMR who underwent implantation of a HeartMate II LVAD as
DT during this period. Since the inception of our multidisciplinary LVAD
program in 2007, LVAD DT was offered only to those who were deemed
inappropriate for CS on the basis of having very poor to no coronary target
vessels to improve myocardial ischemia. The frequency of CS per year was
examined over time (pre- and post-LVAD DT). This study included only
patients with the HeartMate II continuous-flow device (Thoratec, Pleasan-
ton, Calif). All other device types were excluded from this study. All pa-
tients considered for LVAD DT were considered initially for
conventional therapy. Myocardial viability in relation to suitable coronary
targets and probability of mitral surgery were generally assessed first, and
the decision was left to the surgeon’s discretion to refer for advanced heart
failure therapies.
Definitions
The cause of MR was ischemic; all operative and echocardiographic
findings were reviewed in detail for all patients included in this study.The Journal of Thoracic and CarAll patients were deemed to have severe IMR on the basis of leaflet tether-
ing and prior myocardial infarction. Our institutional policy has been to
preserve the posterior leaflet whenever possible with an increasing recent
tendency toward preserving the anterior leaflet and by transposing it to
the posterior annulus at the time of MV replacement. The operative mortal-
ity was defined as death from any cause within 30 days of surgery or during
the same hospitalization. All patients in the MV repair group had the
implantation of an undersized ring/band when applicable. In patients
with mitral repairs, the ring was chosen according to the undersized inter-
commissural distance. In patients with posterior bands, the band was cut
and undersized to the appropriate length. Prolonged intubation was defined
as the need for mechanical ventilation greater than 48 hours. Of note, ex-
tubation protocol was not standardized among groups and left to physician
preferences. Reported postoperative infections include superficial sternal,
urinary tract, and pulmonary infections. Preoperative renal failure was de-
fined as an uncorrected creatinine clearance less than 60 mL/min.
Follow-up
Patients were followed systematically usingmailed questionnaires, tele-
phone interview, or examination at theMayo Clinic. Clinical follow-up was
100% complete. Mean follow-up among survivors was 4.2 years (range,
0-15.7 years).
Statistical Analysis
Mann–Whitney Wilcoxon rank-sum test was used to compare variables
between patients with CS and patients with an LVAD. Categoric variables
between 2 groups were compared using the Fisher exact test. The Kaplan–
Meier method was used to construct survival curves, and survival was
analyzed for both unmatched and matched populations. Differences in sur-
vival between 2 groups were obtained using the log-rank test. Statistical
analysis was performed using R: A language and environment for statistical
computing (R Foundation for Statistical Computing, Vienna, Austria).RESULTS
Patient Characteristics
In this study, 88 patients were identified and had concom-
itant severe ischemic cardiomyopathy and severe IMR.
From 1993 to 2009, 55 patients were labeled to have CS, be-
cause they had a combined CABG and MV (replacement or
repair) procedure. From 2007 to 2011, 33 patients had an
LVAD implanted as DT. The baseline characteristics of all
patients and 2 subgroups according to the type of procedure
(CS vs LVAD DT) are shown in Table 1. The Society of
Thoracic Surgeons predicted mortality for patients in the
CS group was 10.4%. As shown in Table 1, age, preopera-
tive LVEF, incidence of diabetes, and rate of redo surgeries
were comparable between groups (P>.05). However, as ex-
pected, there were significant observed differences between
groups. Compared with patients with CS, patients in the
LVAD DT group had a higher incidence of preoperative re-
nal failure (70% vs 15%, P<.001), a higher rate of preop-
erative intra-aortic balloon pump (IABP) (79% vs 13%,
P<.001), and a higher rate of preoperative inotrope depen-
dency (58% vs 15%, P<.001). Preoperative IABP is fre-
quently used to optimize hemodynamic, right ventricular
function, or kidney function before definitive LVAD ther-
apy. We believe a short bridging (48 hours) strategy
with IABP helps optimize the preoperative condition beforediovascular Surgery c Volume 147, Number 4 1247
TABLE 1. Patient characteristics
CS
n ¼ 55 (%)
LVAD as DT
n ¼ 33 (%)
P
value
Age (y)* 70 (67-75) 71 (67-73) .68
Gender (female) 13 (24) 5 (15) .42
LVEF (%)* 20 (16-23) 20 (15-25) .47
Diabetes 19 (35) 6 (18) .14
Preoperative renal failure 8 (15) 23 (70) <.001
Preoperative inotropes 8 (15) 19 (58) <.001
Preoperative IABP 7 (13) 26 (79) <.001
Redo sternotomy 11 (20) 8 (24) .79
INTERMACS I or II n/a 4 (12) n/a
Lietz–Miller score (mean  SD) n/a 9.3  0.7 n/a
Kormos score (mean  SD) n/a 1.7  0.2 n/a
Matthews score (mean  SD) n/a 1.0  0.2 n/a
CS, Conventional surgery; DT, destination therapy; IABP, intra-aortic balloon pump;
INTERMACS, Interagency Registry for Mechanically Assisted Circulatory Support;
LVAD, left ventricular assist device; LVEF, left ventricular ejection fraction;
n/a, not available; SD, standard deviation. *Age and LVEF are presented using
median with interquartile range for better representation.







Reoperation bleeding 2 (4) 21 (64) <.001
Prolonged intubation 27 (49) 4 (12) <.001
Infection 5 (9) 8 (24) .07
Stroke 2 (4) 3 (9) .36
LOS (d)* 10 (7-16) 18 (13-22) <.001
Mortality (30 d) 4 (7) 1 (3) .65
Mortality (1 y) 12 (22) 5 (15) .58
Follow-up (d)* 931 (174-1600) 341 (209-566) .08
CS, Conventional surgery; DT, destination therapy; LOS, length of stay; LVAD, left
ventricular assist device. *Continuous variables are presented using median with in-
terquartile range.
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(12%, n ¼ 4) were in cardiogenic shock before LVAD
implantation.Operative Details
In the CS group, 44 patients hadMV repair (80%) and 11
patients (20%) had MV replacement. A total of 34 patients
(77%) in the MV repair group had the implantation of an
undersized ring, and 10 patients (23%) received an under-
sized band. In the replacement group, 7 patients (64%) re-
ceived a mechanical valve, and 4 patients (36%) had
a bioprosthesis. The mean number of anastomoses in the
CS group was 2.7 1.3. In the LVADDT group, 33 patients
had a HeartMate II continuous-flow device implanted.Early Comparative Outcomes
We observed significant differences in outcomes compar-
ing both populations (Table 2). Patients in the LVAD DT
groups were more likely to undergo reoperation for bleed-
ing (64% vs 4%, P < .001). Patients in the CS group
were more likely to have a prolonged intubation (49% vs
12%, P<.001). The median length of stay was higher in
the LVAD DT group (18 vs 10 days, P< .001), whereas
the rate of postoperative infection and strokewas similar be-
tween groups (P ¼ .07 and P ¼ .36, respectively). In-
hospital (or 30-day) and 1-year mortality were comparable
between groups. Comparative survival using Kaplan–Meier
analysis revealed no differences in estimated survival be-
tween groups (Figure 1, P ¼ .742). Because of significant
differences in baseline characteristics between groups, we
compared 2 propensity-matched subgroups, controlled for
preoperative differences of renal failure, IABP, and preoper-
ative inotropes. Seventeen patients were identified in each
subgroup. Although the difference in survival did not reach1248 The Journal of Thoracic and Cardiovascular Sura statistical significance (Figure 2, P ¼ .171), we observed
a survival trend favoring the LVAD DT subgroup.
DISCUSSION
There have been several conflicting results in regard to the
benefits of an MV intervention in patients with extremely
low ejection fraction and ischemic cardiomyopathy.11 In
this high-risk population, mitral surgery for severe MR dur-
ing bypass surgery has become the accepted strategy for de-
finitive management of patients with severe ischemic
cardiomyopathy and severe IMR. Fedoruk and colleagues12
reported an observed 8.2% operative mortality with coro-
nary bypass surgery and MV replacement/repair in patients
with extremely lowLVEF. Previously reported results by our
group further suggest an acceptable 84% 1-year and 51%
5-year survival in 179 patients with severe ischemic cardio-
myopathy and severe MR.13 However, reported in-hospital
mortality in this high-risk population has been reported to
be as high as 27%.14 In addition, several groups have ob-
served only a modest improvement in LVEF and New
York Heart Association functional class after surgery.14,15
Dahlberg and colleagues16 further observed that a low
LVEFwas an independent risk factor formortality after con-
comitant CABG and MV surgery. Finally, despite effective
repair using undersized mitral ring annuloplasty, several
groups have reported early recurrence of MR in patients
with LV dysfunction, thus reflecting the complexity of this
disease and its treatment.17-19 We conducted this study to
primarily understand our surgical outcomes in patients
with severe ischemic cardiomyopathy and severe IMR.
Our observed in-hospital or 30-day mortality in patients
with conventional bypass and mitral surgery was 7%, and
the 1-year mortality was 22%. These results compare favor-
ably to other reported series and reaffirm our ability to suc-
cessfully treat these challenging patients with CS.20,21
Implications for Left Ventricular Assist Device as
Destination Therapy
LVADs have become the standard of care for patients
with life-threatening heart failure refractory to optimalgery c April 2014
FIGURE 1. Overall survival. Comparative survival using Kaplan–Meier
analysis revealing no differences in estimated survival between groups
(P ¼ .742). CABG þ MV, Coronary artery bypass grafting þ mitral valve;
LVAD DT, left ventricular assist device destination therapy.
FIGURE 2. Survival in propensity-matched populations. After controlling
for significant preoperative differences betweengroups, propensity-matched
survival analysis did not reach statistical significance (P ¼ .171). CABG þ
MV, Coronary artery bypass graftingþmitral valve; LVAD DT, left ventric-
ular assist device destination therapy.
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a paradigm shift in the use of long-term mechanical support
devices in adult patients with advanced heart failure and
end-stage cardiomyopathy.10 Several patients with ische-
micmyocardial dysfunction and severe ischemicMR are re-
ferred for long-term LVAD, primarily because of poor
coronary targets or nonviability of the myocardium by non-
invasive testing. It is thus reasonable to assess the implica-
tion of both surgical strategies in this high-risk population.
To assess the impact of both therapies, we retrospectively
compared the effectiveness of CS (CABG þ MV surgery)
with LVAD as destination. The patients in the LVAD DT
group, in addition to having no coronary target vessels,
were sicker (Table 1). Despite these differences, survival
was comparable between the CS and LVAD DT groups at
30 days and 1 year (7% vs 3%; 22% vs 15%; P ¼ .65
and P ¼ .58) (Table 2). Within the propensity-matched
population, a trend of improved survival was noted for the
LVAD DT group (Figure 2). Given the small number of
patients, it is not surprising that a statistically significant
difference could not be demonstrated. It is clearly hypothe-
sis generating in that LVADDTmight be preferable over CS
in some appropriately selected subgroup of patients with
advanced ischemic cardiomyopathy. Nevertheless, in the
majority of patients with ischemic cardiomyopathy, CS
composed of coronary bypass and MV repair/replacement
seems to yield outcome comparable to that of LVAD DT.
It now seems these 2 surgical options (CS and LVAD DT)
need to be available as complementary therapy as we care
for the entire spectrum of this challenging group of patients
with advanced ischemic cardiomyopathy.The Journal of Thoracic and CarStudy Limitations
We recognize the retrospective nature of the study. The 2
groups underwent surgery in 2 different time periods with-
out significant overlap, which makes the study more prone
to systemic bias. This patient population represents differ-
ent groups. A better understanding of this patient population
will improve our decision-making process for these chal-
lenging patients. Survival comparisons need to be balanced
with inherent selection differences between groups. Appro-
priate comparisons between these populations is challeng-
ing because conventional preoperative scoring systems are
based on historical cohorts and were designed to address
the specifics of each population without bridging the gap
between surgical strategies. We attempted to correct for
these differences by comparing 2 propensity-matched sub-
groups controlled for preoperative differences of renal fail-
ure, IABP, and preoperative inotropes. There is a need to
develop a standardized preoperative scoring tool to better
stratify patients and evaluate the impact of these 2 therapies.
The median follow-up time also was shorter for patients re-
ceiving an LVAD (341 days) when compared with the
CABGþMV surgery group (931 days). With sufficient sta-
tistical power and long enough follow-up time, the differ-
ence in survival could become significant.CONCLUSIONS
We evaluated surgical results in patients with severe is-
chemic LV dysfunction and severe IMR, and compared
the effectiveness of CS and LVAD as destination. Thediovascular Surgery c Volume 147, Number 4 1249
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acceptable. For those who are inoperable or have prohibi-
tive risks for surgery, LVAD DT can be offered with similar
outcomes. Both of these modalities should be considered as
we evaluate these challenging patients.References
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